The Platform brings together nearly 40 of the leading players in regenerative medicine from across 16 different universities, creating a critical mass of expertise and knowledge. Together they are tackling the major bottlenecks of regenerative medicine to unlock its vast potential and transform healthcare as we know it today.

The Platform comprises of three interdisciplinary and complementary research Hubs. Each Hub has its own broad but distinctive focus, dedicated research team and connections to commercial and clinical end-users. Collectively, they provide a central source of expertise and knowledge – generating new tools, protocols and resources that can be utilised by other research groups in both academia and industry. See an overview of our research hubs here. 



Oversight of the Platform and its progress is provided through a high level independent Programme Board and Executive Group from the Sponsors. The Sponsors also provide the UKRMP Secretariat and Programme Manager. Details are as follows:


Executive Group

Dr Rob Buckle
Chief Science Officer, MRC

Professor Ian Greer
President and Vice Chancellor , Queen’s University Belfast, UK, Chair UKRMP Programme Board

Dr Philippa Hemmings
Head of Healthcare Technologies, EPSRC

Dr David Pan
UKRMP Programme Manager

Professor Melanie Welham
Chief Executive, BBSRC


Programme Board

Professor Ian Greer
(Chair), President and Vice Chancellor , Queen’s University Belfast, UK

Professor Frances Balkwill
Barts Cancer Institute, Queen Mary University of London, UK

Professor Nissim Benvenisty
Director, The Azrieli Centre for Stem Cells and Genetic Research, The Hebrew University of Jerusalem, ISRAEL

Professor Kenneth Boheler
Department of Biomedical Engineering, Johns Hopkins University, USA

Dr Gillian Burgess
Vice President and Site Head UK Research, Vertex

Dr Nigel Burns
Director, Cell Medica

Professor Jöns Hilborn
Head of Polymer Chemistry, Dept of Materials Chemistry, Uppsala University, SWEDEN

Dr Andrew Lynn
CEO, Fluidic Analytics, Cambridge, UK

Professor Marc Peschanski
Scientific Director, Institute for Stem cell Therapy and Exploration of Monogenic diseases, Paris FRANCE

Professor Dr Petra Reinke
Head of Kidney Transplant Outpatient Clinic, Platform D Immune System and GMP-Facility, Berlin-Brandenburg Centre for Regenerative Therapies, GERMANY

Professor Anne Rosser
Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, UK

Assoc Professor Louise van der Weerd
Departments of Radiology & Human Genetics, Leiden University Medical Center, THE NETHERLANDS

Professor Paul Whiting
Chief Scientific Officer Alzheimer’s Research UK/ UCL Drug Discovery Institute UK

Dr Jonathan Appleby
(Observer), Cell and Gene Therapy Catapult, UK

Funded by